These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23666914)

  • 1. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
    Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
    Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
    Mainetti LE; Rozados VR; Rossa A; Bonfil RD; Scharovsky OG
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):151-63. PubMed ID: 20349084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of two metronomic chemotherapy schedules-our experience in the preclinical field.
    Rico MJ; Perroud HA; Mainetti LE; Rozados VR; Scharovsky OG
    Cancer Invest; 2014 Mar; 32(3):92-8. PubMed ID: 24499110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased efficacy and reduced cardiotoxicity of metronomic treatment with cyclophosphamide in rat breast cancer.
    Todorova VK; Kaufmann Y; Klimberg VS
    Anticancer Res; 2011 Jan; 31(1):215-20. PubMed ID: 21273601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
    Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
    Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
    Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
    Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
    Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
    J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
    Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
    Ishida T; Shiraga E; Kiwada H
    J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
    Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma.
    Zavareh S; Mahdi M; Erfanian S; Hashemi-Moghaddam H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1073-1084. PubMed ID: 27752764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vanadium(III)-l-cysteine enhances the sensitivity of murine breast adenocarcinoma cells to cyclophosphamide by promoting apoptosis and blocking angiogenesis.
    Basu A; Bhattacharjee A; Baral R; Biswas J; Samanta A; Bhattacharya S
    Tumour Biol; 2017 May; 39(5):1010428317705759. PubMed ID: 28466788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
    Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
    Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.